MY209603A - Hydroxypyridoxazepines as nrf2 activators - Google Patents
Hydroxypyridoxazepines as nrf2 activatorsInfo
- Publication number
- MY209603A MY209603A MYPI2021004562A MYPI2021004562A MY209603A MY 209603 A MY209603 A MY 209603A MY PI2021004562 A MYPI2021004562 A MY PI2021004562A MY PI2021004562 A MYPI2021004562 A MY PI2021004562A MY 209603 A MY209603 A MY 209603A
- Authority
- MY
- Malaysia
- Prior art keywords
- hydroxypyridoxazepines
- nrf2 activators
- compounds
- relates
- nrf2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806201P | 2019-02-15 | 2019-02-15 | |
| US201962931877P | 2019-11-07 | 2019-11-07 | |
| PCT/IB2020/051100 WO2020165776A1 (en) | 2019-02-15 | 2020-02-11 | Hydroxypyridoxazepines as nrf2 activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY209603A true MY209603A (en) | 2025-07-24 |
Family
ID=69726636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2021004562A MY209603A (en) | 2019-02-15 | 2020-02-11 | Hydroxypyridoxazepines as nrf2 activators |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11945826B2 (https=) |
| EP (1) | EP3924356A1 (https=) |
| JP (1) | JP7602469B2 (https=) |
| KR (1) | KR102932313B1 (https=) |
| CN (2) | CN113474349B (https=) |
| AU (1) | AU2020222080C1 (https=) |
| BR (1) | BR112021016042A2 (https=) |
| CA (1) | CA3129955A1 (https=) |
| CL (1) | CL2021002110A1 (https=) |
| CO (1) | CO2021010930A2 (https=) |
| IL (2) | IL313950A (https=) |
| MA (1) | MA54939A (https=) |
| MX (1) | MX2021009659A (https=) |
| MY (1) | MY209603A (https=) |
| PH (1) | PH12021551873A1 (https=) |
| SG (1) | SG11202108257TA (https=) |
| TW (2) | TWI843806B (https=) |
| WO (1) | WO2020165776A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3833662B1 (en) | 2018-08-20 | 2024-01-17 | Janssen Pharmaceutica NV | Inhibitors of keap1-nrf2 protein-protein interaction |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| KR102932313B1 (ko) * | 2019-02-15 | 2026-02-26 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 활성화제로서 히드록시피리드옥사제핀 |
| AU2020283361B2 (en) * | 2019-05-31 | 2025-11-27 | Ube Corporation | Benzotriazole derivative |
| CN118488944A (zh) | 2022-01-07 | 2024-08-13 | 中外制药株式会社 | 具有Nrf2活化作用的含氮杂环化合物 |
| US20250282724A1 (en) | 2022-04-28 | 2025-09-11 | Daiichi Sankyo Company, Limited | Benzotriazole compound |
| JPWO2023210740A1 (https=) | 2022-04-28 | 2023-11-02 | ||
| EP4580612A1 (en) * | 2022-09-02 | 2025-07-09 | Institut National de la Santé et de la Recherche Médicale | Use of nrf2 activators for the treatment of cerebral small vessel disease |
| CN121152792A (zh) | 2023-06-19 | 2025-12-16 | 中外制药株式会社 | 具有Nrf2活化作用的含氮杂环化合物的晶体 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7714012B2 (en) * | 2006-11-17 | 2010-05-11 | Trustees Of Dartmouth University | Synthesis and biological activities of new tricyclic-bis-enones (TBEs) |
| US9056850B2 (en) * | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
| CN104418834B (zh) * | 2013-08-23 | 2017-09-15 | 重庆博腾制药科技股份有限公司 | 一种抗糖尿病药物中间体的合成方法 |
| SG11201604611SA (en) | 2013-12-18 | 2016-07-28 | Glaxosmithkline Ip Dev Ltd | Nrf2 regulators |
| CN105272960A (zh) * | 2014-07-18 | 2016-01-27 | 上海科胜药物研发有限公司 | 一种坎格列净中间体2-(2-甲基-5-溴苄基)-5-(4-氟苯)噻吩的制备方法 |
| WO2016178148A1 (en) * | 2015-05-05 | 2016-11-10 | Glenmark Pharmaceuticals Limited | Process for preparation of dapagliflozin |
| CA2988373A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| WO2016203401A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| LT3307739T (lt) | 2015-06-15 | 2021-03-10 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 reguliatoriai |
| US10201531B2 (en) * | 2015-08-12 | 2019-02-12 | Mochida Pharmaceutical Co., Ltd. | Indazolyl-oxo-isothiazole compounds |
| US10364256B2 (en) * | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
| US10913762B2 (en) * | 2016-01-27 | 2021-02-09 | Msn Laboratories Private Limited | Process for the preparation of D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl] oxy]phenyl] methyl] phenyl]-, (1S) and its crystalline forms thereof |
| CN108779108A (zh) * | 2016-12-06 | 2018-11-09 | 葛兰素史密斯克莱知识产权发展有限公司 | 3-(2,3-二氢-1h-茚-5-基)丙酸衍生物和它们作为nrf2调节剂的用途 |
| JP2020500918A (ja) * | 2016-12-12 | 2020-01-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２レギュレーターとしてのｎ−アリールピラゾール |
| ES2901617T3 (es) * | 2016-12-14 | 2022-03-23 | Glaxosmithkline Ip Dev Ltd | Bisarilamidas como reguladores de NRF2 |
| CA3044773A1 (en) * | 2016-12-15 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activators |
| KR102932313B1 (ko) * | 2019-02-15 | 2026-02-26 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 활성화제로서 히드록시피리드옥사제핀 |
-
2020
- 2020-02-11 KR KR1020217029193A patent/KR102932313B1/ko active Active
- 2020-02-11 BR BR112021016042-6A patent/BR112021016042A2/pt unknown
- 2020-02-11 JP JP2021547429A patent/JP7602469B2/ja active Active
- 2020-02-11 CA CA3129955A patent/CA3129955A1/en active Pending
- 2020-02-11 EP EP20708180.3A patent/EP3924356A1/en active Pending
- 2020-02-11 AU AU2020222080A patent/AU2020222080C1/en active Active
- 2020-02-11 IL IL313950A patent/IL313950A/en unknown
- 2020-02-11 MA MA054939A patent/MA54939A/fr unknown
- 2020-02-11 US US17/429,088 patent/US11945826B2/en active Active
- 2020-02-11 SG SG11202108257TA patent/SG11202108257TA/en unknown
- 2020-02-11 PH PH1/2021/551873A patent/PH12021551873A1/en unknown
- 2020-02-11 CN CN202080014726.4A patent/CN113474349B/zh active Active
- 2020-02-11 CN CN202410206971.5A patent/CN118206566A/zh active Pending
- 2020-02-11 IL IL285438A patent/IL285438B2/en unknown
- 2020-02-11 WO PCT/IB2020/051100 patent/WO2020165776A1/en not_active Ceased
- 2020-02-11 MX MX2021009659A patent/MX2021009659A/es unknown
- 2020-02-11 MY MYPI2021004562A patent/MY209603A/en unknown
- 2020-02-13 TW TW109104455A patent/TWI843806B/zh active
- 2020-02-13 TW TW113112455A patent/TWI880702B/zh active
-
2021
- 2021-08-11 CL CL2021002110A patent/CL2021002110A1/es unknown
- 2021-08-19 CO CONC2021/0010930A patent/CO2021010930A2/es unknown
-
2024
- 2024-02-27 US US18/588,051 patent/US20240352034A1/en not_active Abandoned
-
2025
- 2025-02-14 US US19/054,254 patent/US20250313573A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102932313B1 (ko) | 2026-02-26 |
| CL2021002110A1 (es) | 2022-02-11 |
| MA54939A (fr) | 2021-12-22 |
| CA3129955A1 (en) | 2020-08-20 |
| TWI843806B (zh) | 2024-06-01 |
| CO2021010930A2 (es) | 2021-09-09 |
| TW202045514A (zh) | 2020-12-16 |
| US20250313573A1 (en) | 2025-10-09 |
| CN113474349A (zh) | 2021-10-01 |
| JP2022520442A (ja) | 2022-03-30 |
| WO2020165776A1 (en) | 2020-08-20 |
| MX2021009659A (es) | 2021-09-08 |
| CN118206566A (zh) | 2024-06-18 |
| TWI880702B (zh) | 2025-04-11 |
| CN113474349B (zh) | 2024-03-01 |
| US20240352034A1 (en) | 2024-10-24 |
| US11945826B2 (en) | 2024-04-02 |
| AU2020222080C1 (en) | 2022-09-29 |
| IL313950A (en) | 2024-08-01 |
| IL285438B2 (en) | 2024-12-01 |
| US20220204526A1 (en) | 2022-06-30 |
| AU2020222080B2 (en) | 2022-05-19 |
| TW202440593A (zh) | 2024-10-16 |
| IL285438B1 (en) | 2024-08-01 |
| PH12021551873A1 (en) | 2022-05-23 |
| BR112021016042A2 (pt) | 2021-10-05 |
| EP3924356A1 (en) | 2021-12-22 |
| JP7602469B2 (ja) | 2024-12-18 |
| KR20210126676A (ko) | 2021-10-20 |
| SG11202108257TA (en) | 2021-08-30 |
| IL285438A (en) | 2021-09-30 |
| AU2020222080A1 (en) | 2021-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551873A1 (en) | Hydroxypyridoxazepines as nrf2 activators | |
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| ZA202206923B (en) | New methylquinazolinone derivatives | |
| MD20170016A2 (ro) | Compuşi aminopirimidinici ca inhibitori JAK | |
| GEP201606555B (en) | Compounds and compositions for modulating egfr activity | |
| MX2022013612A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas. | |
| PH12017500281B1 (en) | Pyrrolopyrimidine compounds used as tlr7 agonist | |
| SG10201811384TA (en) | Mnk inhibitors and methods related thereto | |
| TN2017000535A1 (en) | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| SG10201906942PA (en) | Piperidine cxcr7 receptor modulators | |
| MX2024013464A (es) | Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos | |
| MX2016016516A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
| SA522431777B1 (ar) | مشتقات ألفا -d- جالاكتو بيرانوسيد | |
| PH12022550338A1 (en) | 2-hydroxycycloalkane-1-carbamoyl derivatives | |
| MX2016016530A (es) | Inhibidores de fosfatidilinositol 3-quinasa. | |
| TN2017000485A1 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
| MY194116A (en) | Pharmaceutical compounds | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| PH12018500377A1 (en) | Novel annelated benzamides | |
| MX389786B (es) | Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer. | |
| PH12018500378A1 (en) | Novel annelated phenoxyacetamides | |
| NZ762437A (en) | Novel heterocyclic compounds as cdk8/19 inhibitors | |
| MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
| PH12022551241A1 (en) | Egfr inhibitors |